List of Bioinformatics Companies in Texas - 17

Accel Diagnostics is medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions. We are dedicated to making a difference in the quality of life of millions of patients through technology and innovation. AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests anytime and anywhere. The Company's patented platform technology transforms the patient blood testing paradigm, from lab-centered to near-patient. The technology bringing significant advantages in terms of simplicity, time to result, care delivery, and cost over current standard lab-based diagnostics. During COVID-19 pademic Accel Diagnostics began to operate the ADX Diagnostic Lab to provide high quality COVID testing in Houston, TX.

AyuVis is a start-up biopharmaceutical company focusing on developing New Molecular Entities (NME) as immune modulating, anti-microbial, and anti-inflammatory drugs. Our pipeline of drug candidates is based on a new platform technology that modulates macrophages in the innate immune system to restore balance while fighting both infection and inflammation. Stimulating these macrophages produces a rapid therapeutic response throughout the body as we have seen in our strong preclinical data. This is unlike any existing immunotherapies today - immunotherapies which in total have annual sales of $70B. Because the antimicrobial action of our compounds is through the activation of phagocytosis, the development of multidrug resistance is not anticipated. Our goal is to save and improve lives, reduce hospital costs, & provide an effective treatment to diseases like BPD, VAP, and ARDS with no adverse side effects that are seen with the current alternatives. Our lead candidate is Orphan Drug and Rare Pediatric Disease Designated by the US FDA for the prevention of bronchopulmonary dysplasia (BPD) in at-risk preterm infants. BPD is a rare pediatric lung disease in preterm babies caused by inflammation from supplemental oxygen required for survival in the NICU and is the second leading cause of death in preterm babies. An average of 112 preterm babies die per month in the US due to the lack of an effective therapy and survivors require ongoing care. AyuVis has 2 patents approved by the USPTO and more countries which include composition of matter of our compounds, methods of use, formulations, and more.

Base Pair Biotechnologies, Inc. offers rapid discovery of high quality aptamer (DNA- and RNA-based) affinity ligands. Aptamers have been successfully employed in virtually every application where antibodies are typically used. Aptamers have a number of potential advantages over antibodies, however, in a variety of applications. Base Pair Bio's aptamer discovery is powered by a patented, multiplexed approach to aptamer identification. This and other chemical enhancements result in better DNA affinity ligands. For more information, please visit www.basepairbio.com.

CellChorus conducts dynamic single-cell analysis at scale. Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) uses visual AI to evaluate how cells exist in motion. CellChorus is a single-cell, visual AI company that is the leader in visual AI for single-cell analysis.

MAVEvidence is the premier functional evidence resource for the clinical genetics community. MAVEvidence delivers increased productivity and time savings through comprehensive curation, rigorous analysis, and clear presentation of functional evidence derived from high-throughput studies of genetic variants. The MAVEvidence platform contains more than 187,000 pieces of evidence across 125,000 genetic variants, and is continually updated with data from the latest functional studies.

FAR Biotech is a preclinical, computational drug discovery company that focuses on hard-to-drug targets that have high scientific and commercial value. Founded by Dr Martin Martinov after 25 years in academia and industry -- and named after the Bulgarian word “far” that translates into “lighthouse” or “beacon” -- FAR seeks to shine a light on drug discovery in areas of high unmet clinical need. FAR's proprietary technology can more rapidly identify novel, structurally diverse, optimized, lead molecules that other approaches would not look for, let alone find. The key differentiator is FAR's complete and rigorous quantum mechanical representation of drug-target interactions -- which embeds the advantages of quantum similarity and multi-property optimization for hit and lead identification -- augmented by AI / machine learning & big data. FAR's quantum biomodelling platform has been validated preclinically across a number of therapeutic areas, including neurodegeneration, oncology and infectious diseases.

Form empowers scientists to harness the data, computing power and collaboration that drive how today's breakthroughs are made.

A premier research institution providing global genomic profiling and molecular diagnostics services to academic centers, pharmaceutical and biotech industry, oncologists, and pathologists with innovative diagnostic, prognostic, predictive, and personalized testing. Genome Explorations, a Tesis Biosciences company, is a state of the art CLIA certified GLP compliant Lab providing NextGen sequencing, Genotyping, Gene Expression and microRNA profiling services. Our Clients range from Fortune 500 Pharmaceutical and Biotech to Individual Investigators at Academic institutes and are located worldwide. Our experienced scientists work one-on-one with researchers and clinicians to provide a ‘Complete Solution' for all their Research and Clinical needs, from experimental design to in-depth data analysis and advanced bioinformatics. Genome Explorations also offers ‘Complete Solutions' for challenging specimens, such as whole blood and FFPE tissues.

GenrAb, Inc. is harnessing the power of adaptive human immunity to discover neuroprotective and neurotherapeutic human antibodies. Guided by proprietary immunogenetic models, the Company interrogates the cerebrospinal fluid in patients with active neurological disease to harvest novel human disease associated antibodies. Antibodies such as TGM-010, are selected based on their antineuronal capabilities and potential for managing neuronal stress to preserve cell function and survival. Using this unique approach, GenrAb is building a pipeline of patented therapeutic antibodies that can durably reduce disability in patients suffering from neurodegenerative disease, democratizing the availability of even rare antibodies found only in certain patients with neurological disease. GenrAb has been the recipient of multiple accolades, recently featured in the Dallas Morning News, as the North Texas Therapeutics Innovator of the Year, a Texas Biotech Rising Star while winning multiple Golden Ticket awards in highly competitive environments that were sponsored by Boehringer-Ingelheim ('23), and Otsuka Pharmaceuticals ('24).

Inform Diagnostics, a Fulgent Genetics Company, is a leading pathology laboratory trusted by clinicians throughout the U.S. We provide timely, accurate and definitive patient diagnoses in the fields of dermatopathology, gastrointestinal pathology, hematopathology, neuropathology, breast pathology, molecular diagnostics (Covid-19 testing), and genitourinary pathology. Working for Inform Diagnostics means you will contribute alongside top multidisciplinary talent in an environment with cutting-edge tools and breakthrough technologies. It is a place where people are passionate in their belief that every patient deserves the right answer. Driven by an unwavering dedication to quality, Inform Diagnostics profoundly impacts patient care, one diagnosis at a time. The company has state-of-the-art laboratories in Boston, Dallas, New York City, and Phoenix. Visit us at informdx.com.  

Kiromic BioPharma is an allogeneic Gamma Delta T-cell therapy company featuring unique, proprietary, end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors. We are a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic’s DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

LC Sciences is a global biotechnology company providing products and services to genomics and proteomics researchers across an array of markets for nucleic acid/protein analysis, biomarker-discovery and drug development. Our innovative products and comprehensive services are based on several unique, core technology platforms developed by the scientists here at LC Sciences. A wide range of microarray service products are based on our µParaflo® microfluidic on-chip synthesis technology. This technology enables us to provide unique and customizable arrays of oligonucleotides, peptides, and their analog molecules. Our line of microarray services includes microRNA profiling, custom oligonucleotide (aptamer) screening, and peptide arrays for epitope mapping, protein kinase substrate profiling, and phosphopeptide binding assays. The OligoMix® technology has significantly reduced the cost and increased the speed of highly multiplexing genome-scale experiments such as exploration of small RNAs and designer gene/DNA library synthesis. OligoMix® technology has been applied to library construction of various biomolecules, sequence capture for targeted next-gen sequencing, and synthetic biology. The recently developed OligoFix™ strategy for error correction of microarray synthesized oligos has greatly improved the utility of OligoMix® for synthetic biology applications. The game-changing VariantPro™ multiplex-PCR based targeted sequencing system provides a simple, robust process delivering cost savings due to improved sequencing efficiency. Unlike singleplex methods with limited scalability and inflexible or traditional multiplex methods that suffer from primer induced variation in coverage requiring additional sequencing depth, VariantPro™ combines the specificity of a singleplex PCR reaction with the scalability of a multiplex reaction into a single step via relay-PCR, requiring less sequencing depth per sample.

Rice University is a Higher Education institution that offers a range of undergraduate and graduate programs, and is known for its research initiatives.

RTLGenomics is a full service sequencing company offering sequencing approaches including barcoding, metagenomicsand transcriptomics. A sister lab, MicroGen, is a CAP accredited clinical diagnostic laboratory.

Signature Science's consultants serve government and commercial clients through a wide array of technical offerings. We combine scientific rigor with proven quality assurance processes to deliver solution-focused, well-executed projects and contracts. Our expertise enhances the credibility and defensibility of government programs that provide for our national and homeland security. The knowledge and experience of our consultants span a wide array of disciplines that match the technical needs of clients and the management requirements of our business. We have credentials in chemistry, biology, microbiology, biochemistry, forensic science, statistics, data science, quality assurance, engineering, physics, and management.

At Solugen, we believe planet-scale change starts with the chemistry we use every day. We’re revolutionizing how things are made with the world’s first carbon negative molecule factory: the Bioforge. Harnessing the power of evolved enzymes, plant-based feedstocks, and clean, catalytic reactions, we are making the materials we need to sustain life on Earth—faster, cheaper, and without emissions or waste.

Southwest Research Institute is an independent, nonprofit, applied research and development organization. The staff numbers approximately 3,000 professionals specializing in the creation and transfer of technology in engineering and the physical sciences. Research volume for fiscal year 2021 was nearly $726 million. SwRI headquarters occupy more than 1,500 acres in San Antonio, Texas, and provide more than 2.3 million square feet of laboratories, test facilities, workshops, and offices. SwRI maintains technical offices and laboratories in Ann Arbor, Mich.; Beijing, China; Boulder, Colo.; Hanover and Rockville, Md.; Ogden, Utah; Minneapolis, Minn.; Oklahoma City; Warner Robins, Ga.; and Durham, N.H. SwRI is an independent organization. Likes, follows, and shares do not imply endorsements.